Author response for "Effect of Lixisenatide on Natriuretic Peptides in People With Type 2 Diabetes And Recent Acute Coronary Syndrome: The ELIXA Trial" — Hertzel C. Gerstein (2022) | RDL Network
Author response for "Effect of Lixisenatide on Natriuretic Peptides in People With Type 2 Diabetes And Recent Acute Coronary Syndrome: The ELIXA Trial"
Hertzel C. Gerstein, Emil Wolsk, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Sibylle Hess, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer
Hertzel C. Gerstein, Emil Wolsk, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Sibylle Hess, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer
Marc A. Pfeffer, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Hertzel C. Gerstein, Lars Køber, Francesca Lawson, Ping Lin, Xiaodan Wei, Eldrin F. Lewis, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Scott D. Solomon, Jean‐Claude Tardif
Marc A. Pfeffer, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Hertzel C. Gerstein, Lars Køber, Francesca Lawson, Lin Ping, Xiaodan Wei, Eldrin F. Lewis, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Scott D. Solomon, Jean‐Claude Tardif
Hertzel C. Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer
Discussion(0)
No comments yet. Be the first to comment.